-
1 Comment
Innovent Biologics, Inc is currently in a long term uptrend where the price is trading 5.4% above its 200 day moving average.
From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.0.
Finally, its free cash flow fell by 0.2% to $-372M since the same quarter in the previous year.
Based on the above factors, Innovent Biologics, Inc gets an overall score of 2/5.
| CurrencyCode | EUR |
|---|---|
| ISIN | KYG4818G1010 |
| Exchange | F |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Target Price | None |
| Market Cap | 14B |
| Beta | 0.23 |
| Dividend Yield | None |
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverematinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), Dupert (fulzerasib), DOVBLERON (taletrectinib), Jaypirca (pirtobrutinib), limertinib, and SYCUME (teprotumumab N01 injection). The company is also developing three new drugs, which are under regulatory review; four assets in Phase 3 and pivotal clinical trials; and 15 molecules in early clinical stage. In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 6IB.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
